<div class="safety2">
	<h1><a href="#">Trust a Benefit-Risk Profile <br/>with Proven Protection</a></h1>
	<p>AF patients on Xarelto benefit from better overall protection: <br/>
	superior efficacy and demonstrated safety<em>Multiple points of protection with Xarelto<sup>&reg;</sup></em>
	</p>
	<div class="safety0"></div>
	<div class="ref bottom" id="safety_zoom2">
		<p><strong><sup>a</sup>Major + Non-major clinically relevant bleeding:</strong> event rate per 100 patient-years (14.91 vs 14.52).<br />
			 <strong><sup>b</sup>Major bleeding:</strong> bleeding associated with a ≥2 g/dL fall in haemoglobin or requirement for transfusion of ≥2 units of packed
		red blood cells or whole blood (clinically overt bleeding); the involvement of a critical site; or a fatal outcome. Event rate per 100
		patient-years (3.60 vs 3.45).<br />
		<strong><sup>c</sup>Non-major clinically relevant bleeding:</strong> overt bleeding not meeting the criteria for major bleeding but associated with
		medical intervention; unscheduled contact with a physician; temporary study drug cessation; pain; or impairment of daily activities.
		Event rate per 100 patient-years (11.80 vs 11.37).</p>
	</div>
</div>
